208 related articles for article (PubMed ID: 25051026)
1. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
2. Prodrug Strategies for the Development of β-l-5-((
Singh US; Konreddy AK; Kothapalli Y; Liu D; Lloyd MG; Annavarapu V; White CA; Bartlett MG; Moffat JF; Chu CK
J Med Chem; 2023 May; 66(10):7038-7053. PubMed ID: 37140467
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
5. The development of BVDU: An odyssey.
De Clercq E
Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
[TBL] [Abstract][Full Text] [Related]
6. A Novel Human Skin Tissue Model To Study Varicella-Zoster Virus and Human Cytomegalovirus.
Lloyd MG; Smith NA; Tighe M; Travis KL; Liu D; Upadhyaya PK; Kinchington PR; Chan GC; Moffat JF
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878893
[TBL] [Abstract][Full Text] [Related]
7. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
8. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
9. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.
Rowe J; Greenblatt RJ; Liu D; Moffat JF
Antiviral Res; 2010 Jun; 86(3):276-85. PubMed ID: 20307580
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
Choi Y; Li L; Grill S; Gullen E; Lee CS; Gumina G; Tsujii E; Cheng YC; Chu CK
J Med Chem; 2000 Jun; 43(13):2538-46. PubMed ID: 10891113
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
12. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and mode of inhibition of varicella-zoster virus by L-beta-5-bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil is dependent on viral thymidine kinase.
Li L; Dutschman GE; Gullen EA; Tsujii E; Grill SP; Choi Y; Chu CK; Cheng YC
Mol Pharmacol; 2000 Nov; 58(5):1109-14. PubMed ID: 11040060
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
15. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
16. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.
Balzarini J; McGuigan C
J Antimicrob Chemother; 2002 Jul; 50(1):5-9. PubMed ID: 12096000
[TBL] [Abstract][Full Text] [Related]
17. Herpes zoster guideline of the German Dermatology Society (DDG).
Gross G; Schöfer H; Wassilew S; Friese K; Timm A; Guthoff R; Pau HW; Malin JP; Wutzler P; Doerr HW
J Clin Virol; 2003 Apr; 26(3):277-89; discussion 291-3. PubMed ID: 12637076
[TBL] [Abstract][Full Text] [Related]
18. Development of Robust Varicella Zoster Virus Luciferase Reporter Viruses for In Vivo Monitoring of Virus Growth and Its Antiviral Inhibition in Culture, Skin, and Humanized Mice.
Lloyd MG; Yee MB; Flot JS; Liu D; Geiler BW; Kinchington PR; Moffat JF
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458556
[TBL] [Abstract][Full Text] [Related]
19. Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus.
Weber O
Antivir Chem Chemother; 2000 Jul; 11(4):283-90. PubMed ID: 10950390
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Balzarini J; McGuigan C
Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
